Headline Therapeutic focus - Huntexil at spout of dry Huntington's disease pipeline
Source EP Vantage
Company NeuroSearch, Lupin, Neurocrine Biosciences, Novartis, Pfizer, Proneuron Biotechnologies, Teva Pharmaceutical Industries 
Date February 04, 2010
 

NeuroSearch’s release of positive phase III data on its Huntington’s disease drug, Huntexil, was an encouraging development for patients but also demonstrated how dry the pipeline is for this neurodegenerative condition.

Huntexil, a dopaminergic stabiliser, is the first of two candidates currently in phase III trials to announce results, the other being Medivation's Dimebon. Behind that only one candidate is reported to be in phase II, where it has lingered since 2003 and has been the subject of a legal tussle between the research partners, Teva and Proneuron, over trials for amyotrophic lateral sclerosis (ALS).
 

This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
EP Vantage SM ©2010 EP Vantage Ltd